<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765646</url>
  </required_header>
  <id_info>
    <org_study_id>P0160</org_study_id>
    <nct_id>NCT02765646</nct_id>
  </id_info>
  <brief_title>eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX Arteries</brief_title>
  <acronym>eTRYTONLM</acronym>
  <official_title>eTryton Left Main Multi-center, Prospective, Non-randomized Single Arm Registry Evaluating the Tryton Side Branch Stent® for Treatment of de Novo CAD in Both LM and Circumflex (LCX) Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tryton Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tryton Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate the clinical performance of the Tryton Side&#xD;
      Branch Stent used in conjunction with a commercially available Drug Eluting Stent (DES) to&#xD;
      treat de novo bifurcated lesions involving both the Left Main (LM) and Circumflex Coronary&#xD;
      Artery(LCX).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The registry study will involve the collection of demographic and clinical data, including&#xD;
      in-hospital and follow-up data to determine primary composite endpoint of MACE (Major Adverse&#xD;
      Cardiac Events) at 9 months and secondary endpoints. Secondary endpoints are defined as&#xD;
      successful deployment of the Tryton stent and main vessel DES within the target lesion,&#xD;
      angiographic success &lt;30% residual stenosis in LM and LAD/LCX by visual estimate and TIMI 3&#xD;
      flow post procedure, and freedom of in-hospital MACE.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>MACE: cardiac death, non-index procedure related myocardial infarction, TLR, definite stent thrombosis</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural success: successful deployment of Tryton stent and MV DES within target lesion, Angiographic success &lt;30% residual stenosis in LM and LAD/LCX bifurcation by visual est. and TIMI flow 3 post procedure and freedom of in-hospital MACE</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical endpoints: MACE: total death, cardiac death, non-index procedure related MI, Target lesion revascularization (TLR), Target vessel revascularization (TVR), definite stent thrombosis, Procedure related MI</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Left Main Coronary Artery Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary stent procedure (CSP)</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CAD due to de novo stenotic lesion in the distal part of the LM at the&#xD;
        bifurcation of the Left Anterior Descending Artery (LAD) and the Left Circumflex (LCX)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is ≥18 years old;&#xD;
&#xD;
          2. Patient is eligible for percutaneous coronary intervention (PCI);&#xD;
&#xD;
          3. Patient is an acceptable candidate for CABG;&#xD;
&#xD;
          4. Clinical evidence of ischemic heart disease and / or a positive functional registry.&#xD;
             Documented stable angina pectoris (Canadian cardiovascular society classification&#xD;
             (CCS) 1, 2, 3 or 4), unstable angina pectoris (Braunwald Class IB-C, IIB-C, or&#xD;
             IIIB-C), or documented silent ischemia;&#xD;
&#xD;
          5. Single high grade de novo bifurcation lesion with ≥50% and &lt;100% stenosis in the&#xD;
             distal part of left main, requiring stent placement across LCx Ostium, with TIMI flow&#xD;
             &gt; 2 by visual estimation;&#xD;
&#xD;
          6. The target lesion length must be able to be covered by a single main vessel stent ≥&#xD;
             5.0mm and ≤ 32 mm in the main vessel and ≤ 32 mm in the side branch (visual estimate)&#xD;
             and be covered by one Tryton stent and up to one DES in the side branch;&#xD;
&#xD;
          7. The reference vessel diameter of the main branch must be ≥ 2.5mm and ≤ 4.0 mm (visual&#xD;
             estimate) and reference vessel diameter of the side branch must be ≥ 2.25mm and ≤ 3.5&#xD;
             mm (visual estimate);&#xD;
&#xD;
          8. If required by local regulations, the patient had been informed of the nature of the&#xD;
             registry, agrees to its provisions and has provided written informed consent, approved&#xD;
             by the appropriate Medical Ethics Committee (MEC) of the respective clinical site;&#xD;
&#xD;
          9. The patient is willing to comply with follow-up evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female of childbearing potential;&#xD;
&#xD;
          2. Documented left ventricular ejection fraction (LVEF) ≤30%;&#xD;
&#xD;
          3. Evidence of an acute myocardial infarction within 48 hours of the intended treatment;&#xD;
&#xD;
          4. Known allergies to the following: Acetylsalicylic acid (ASA) (Aspirin®), Clopidogrel&#xD;
             bisulfate (Plavix®.) or Ticlopidine (Ticlid®.), Heparin, contrast agent (that cannot&#xD;
             be adequately pre-medicated);&#xD;
&#xD;
          5. Acute or chronic renal dysfunction (serum creatinine &gt;2.0 mg/dl or &gt;150μmol/L);&#xD;
&#xD;
          6. Target vessel has angiographic evidence of thrombus;&#xD;
&#xD;
          7. Previous interventional procedure (less than 1 year) anywhere within the left main&#xD;
             artery including the bifurcation to the LAD and/or LCX;&#xD;
&#xD;
          8. Anticipated use of rotational atherectomy&#xD;
&#xD;
          9. Significant (&gt;50%) stenosis proximal or distal to the target lesion that might require&#xD;
             revascularization or impede run offCONFIDENTIAL Page 7 of 18 August 11, 2015 - version&#xD;
             5 that will not be treated during the index procedure;&#xD;
&#xD;
         10. Heavily calcified lesion and/or calcified lesion which cannot be successfully&#xD;
             predilated;&#xD;
&#xD;
         11. Prior stent in the Left Main;&#xD;
&#xD;
         12. Prior stent within 5mm distal of the target lesion;&#xD;
&#xD;
         13. Total occluded dominant RCA;&#xD;
&#xD;
         14. Trifurcation lesion with a Ramus Intermedius diameter of &gt;2.0 mm; a Diagonal Branch&#xD;
             diameter of &gt;2.0 mm within 5 mm of LAD origin; a Obtuse Marginal &gt;2.0 mm diameter&#xD;
             within 5 mm of LCx origin;&#xD;
&#xD;
         15. Patient is currently participating in an investigational drug or device registry that&#xD;
             has not completed the primary endpoint or that clinically interferes with the current&#xD;
             registry endpoints.&#xD;
&#xD;
         16. Stroke or transient ischemic attack within the prior 6 months;&#xD;
&#xD;
         17. In the Investigator's opinion patient has a co-morbid condition(s) that could limit&#xD;
             the patient's ability to participate in the registry, compliance with follow-up&#xD;
             requirements or impact the scientific integrity of the registry;&#xD;
&#xD;
         18. Recipient of heart transplant;&#xD;
&#xD;
         19. Life expectancy less than 1 year;&#xD;
&#xD;
         20. Braunwald Class IA, IIA and IIA angina pectoris;&#xD;
&#xD;
         21. Patients with severe congestive heart failure;&#xD;
&#xD;
         22. Patients with severe heart failure NYHA IV;-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stylianos A Pyxaras, MD,FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum-Coburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Cobury GmbH</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

